Acute Myeloid Leukemia Clinical Trials

A listing of 170 Acute Myeloid Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Acute Myeloid Leukemia

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 170 active clinical trials seeking participants for Acute Myeloid Leukemia research studies. The states with the highest number of trials for Acute Myeloid Leukemia participants are California, New York, Illinois and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Clinical Study

Recruiting

We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.

Conditions:

Cough

Chronic Cough

Asthma

Allergic Asthma

Sinusitis

Learn More

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Learn More

Featured Trial

Healthy Volunteer Clinical Studies

Recruiting

Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.

Conditions:

Healthy

Healthy Volunteers

Learn More

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847

Recruiting

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have six groups or "parts." Part A will find out how much SEA-CD70 should be given to patients. Part B will use the dose found in Part A... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/20/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +22 locations

University of Alabama at Birmingham, Birmingham, Alabama

City of Hope, Duarte, California

UCLA Department of Medicine - Hematology & Oncology, Los Angeles, California

Colorado Blood Cancer Institute, Denver, Colorado

University of Kansas Cancer Center, Fairway, Kansas

Norton Cancer Institute, Louisville, Kentucky

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Karmanos Cancer Institute / Wayne State University, Detroit, Michigan

San Juan Oncology Associates, Farmington, New Mexico

Columbia University Medical Center, New York, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Cleveland Clinic, The, Cleveland, Ohio

James Cancer Hospital / Ohio State University, Columbus, Ohio

Medical University of South Carolina/Hollings Cancer Center, Charleston, South Carolina

Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina

Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee

Texas Oncology - Fort Worth, Dallas, Texas

Houston Methodist Cancer Center, Houston, Texas

MD Anderson Cancer Center / University of Texas, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

Leids Universitair Medisch Centrum ( LUMC), Leiden, Other

University Medical Center (UMC) Utrecht, Utrecht, Other

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Learn More ›

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

NCT06285890

Recruiting

To find a recommended dose of HC-7366 that can be given in combination with azacitidine and venetoclax to patients with AML. The safety and effects of this drug combination will also be studied.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/20/2024

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia

Learn More ›

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

NCT05153330

Recruiting

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/16/2024

Locations: University of California, Irvine, Irvine, California +40 locations

University of California, Irvine, Irvine, California

University of Southern California Norris Cancer Center, Los Angeles, California

UCLA Department of Medicine, Los Angeles, California

UC Davis Comprehensive Cancer Center, Sacramento, California

Stanford Cancer Center, Stanford, California

Mayo Clinic, Jacksonville, Florida

Mount Sinai Medical Center, Miami Beach, Florida

Moffitt Cancer Center, Tampa, Florida

Blood & Marrow Transplant Group of GA (Northside Hospital), Atlanta, Georgia

Northwestern University, Chicago, Illinois

Henry Ford Hospital, Detroit, Michigan

University of Cincinnati Medical Center, Cincinnati, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Vanderbilt University Medical Center, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Virginia Cancer Specialists, Gainesville, Virginia

Evangelismos General Hospital of Athens, Athens, Not set

Alexandra General Hospital of Athens, Athens, Not set

AOU Ospedali Riuniti Ancona, Ancona, Not set

ASST Papa Giovanni XXIII Hospital Bergamo, Bergamo, Not set

Istituto Europeo di Oncologia, Milano, Not set

Instituto Clinico Humanitas, Milan, Not set

IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC, Milan, Not set

Ospedale Santa Maria della Misericordia, Perugia, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Not set

Amsterdam UMC, Amsterdam, Not set

UMCG Groningen, Groningen, Not set

Radboud University Medical Center, Nijmegen, Not set

Erasmus University Medical Center Rotterdam, Rotterdam, Not set

Hospital General de Albacete, Albacete, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Institut Catala d'Oncologia, Barcelona, Not set

Hospital San Pedro de Alcántara, Cáceres, Not set

Hospital Universitario de la Princesa, Madrid, Not set

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Central de Asturias, Oviedo, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Hospital Universitario y Politécnico La Fe, Valencia, Not set

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828

Recruiting

This phase I/II pilot study aims to enhance the effectiveness of stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). Patients will undergo a stem cell transplant from a half-matched family donor. One week later, patients will receive an additional infusion of immune cells and a drug called interleukin-2. To mitigate the potential complications associated with graft-versus-host-disease, the donated stem cell product undergoes a process that removes a s... Read More

Gender:

All

Ages:

All

Trial Updated:

05/16/2024

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia

Learn More ›

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Recruiting

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

Gender:

All

Ages:

30 days and above

Trial Updated:

05/15/2024

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +47 locations

City of Hope Comprehensive Cancer Center, Duarte, California

University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital, Los Angeles, California

Stanford Cancer Institute, Palo Alto, California

University of Colorado, Aurora, Colorado

Florida Cancer Specialists and Research Institute, Sarasota, Florida

Moffitt Cancer Center, Tampa, Florida

Emory Winship Cancer Institute, Atlanta, Georgia

Children's Healthcare of Atlanta, Atlanta, Georgia

The University of Chicago Medical Center, Chicago, Illinois

University of Iowa hospital, Iowa City, Iowa

Dana Farber Cancer Institute, Boston, Massachusetts

Washington University in St. Louis School of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Memorial Sloan Kettering Cancer Center, New York, New York

Montefiore Medical Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati, Cincinnati, Ohio

Ohio State University, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

University of Pennsylvania, Philadelphia, Pennsylvania

The University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Peter MacCallum Cancer Centre (PMCC), Melbourne, Victoria

Royal Melbourne Hospital (RMH), Parkville, Victoria

Alfred Hospital, Melbourne, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Royal North Shore Hospital, Saint Leonards, Not set

University Health Network, Toronto, Not set

The Hospital for Sick Children, Toronto, Not set

Centre Hospitalier Lyon Sud, Pierre-Benite, Not set

Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP, Villejuif, Not set

Universitaetsklinikum Essen (AoR), Essen, Not set

Universitaetsmedizin Greifswald, Greifswald, Not set

Universitaetsmedizin Der Johannes, Gutenberg, Not set

Rambam Health Care Campus (RHCC, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah Medical Center- Ein Kerem, Jerusalem, Not set

Galilee Medical Center, Nahariya, Not set

Rabin Medical Center, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Not set

Istituto Romagnolo Per Lo Studio dei tumori Dino Amadori, Meldola, Not set

S Bortolo Hospital AULSS 8 Berica, Vicenza, Not set

Vilnius University Hospital Santaros Klinikos, Vilnius, Not set

Princess Maxima Center for Pediatric Oncology, Utrecht, Not set

Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals, Hospitalet De Llobregat, Not set

Hospital Universitario Virgen del Rocio, Seville, Not set

Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Not set

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage

Learn More ›

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

NCT05735184

Recruiting

This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/15/2024

Locations: Moores UC San Diego Cancer Center, La Jolla, California +27 locations

Moores UC San Diego Cancer Center, La Jolla, California

USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California

UCLA - Bowyer Oncology Center, Los Angeles, California

UCI Health Chao Family Comprehensive Cancer Center, Orange, California

UC Health Blood Disorders and Cell Therapies Center - Anschutz Medical Campus, Aurora, Colorado

Colorado Blood Cancer Institute, Denver, Colorado

Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

The University of Kansas Cancer Center, Fairway, Kansas

Norton Cancer Institute - St. Matthews, Louisville, Kentucky

Ochsner MD Anderson Cancer Center, Jefferson, Louisiana

Massachusetts General Hospital, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

University of Minnesota, Minneapolis, Minnesota

Rutgers Cancer Institute, New Brunswick, New Jersey

Roswell Park Comprehensive Cancer Center, Buffalo, New York

New York - Presbyterian / Weill Cornell Medicine, New York, New York

Mount Sinai - Ruttenberg Treatment Center, New York, New York

Stony Brook Cancer Center, Stony Brook, New York

Duke Blood Cancer Center, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

TriStar Bone Marrow Transplant, Nashville, Tennessee

Sarah Cannon Research Institute - St. David's South Austin Medical Center / Texas Oncology South Austin, Austin, Texas

UT Southwestern - Simmons Cancer Center, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

UW Health - Carbone Cancer Center, Madison, Wisconsin

Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma

Learn More ›

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

NCT04062266

Recruiting

This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in chemotherapy, such as azacitidine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Gender:

All

Ages:

18 years and above

Trial Updated:

05/13/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Minimal Residual Disease Persistence, Therapy-Related Acute Myeloid Leukemia, Acute Myeloid Leukemia

Learn More ›

Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia

NCT03573024

Recruiting

This study aims to treat non-elderly adult patients, who were previously untreated for acute myeloid leukemia, using venetoclax and azacitidine.

Gender:

All

Ages:

Between 18 years and 59 years

Trial Updated:

05/13/2024

Locations: Universtiy of Colorado Hospital, Aurora, Colorado

Conditions: Acute Myeloid Leukemia

Learn More ›

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

NCT04128501

Recruiting

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem c... Read More

Gender:

All

Ages:

Between 18 years and 75 years

Trial Updated:

05/13/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia

Learn More ›

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

NCT05800210

Recruiting

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMA... Read More

Gender:

All

Ages:

Between 6 months and 39 years

Trial Updated:

05/07/2024

Locations: University of Florida, Gainesville, Florida

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin

Learn More ›

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

NCT03589729

Recruiting

This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants... Read More

Gender:

All

Ages:

12 years and above

Trial Updated:

05/07/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Myeloid Sarcoma, Myeloproliferative Neoplasm, Philadelphia Chromosome Positive

Learn More ›

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

NCT04128748

Recruiting

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

05/07/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome

Learn More ›